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in the assumptions.CONCLUSIONS:Comparedwith usual therapeutic strategies of
anemia, the use of intravenous iron appears to be significantly cost saving in che-
motherapy-induced anemia in breast cancers and gastrointestinal cancers.
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OBJECTIVES: The objective of this study was to determine, from the perspective of
PMH, the financial impact of treating patients with CLL using R and intravenous FC
(R-FC IV) versus R and orally administered FC (R-FC PO).METHODS: A cost analysis
was performed from the perspective of PMH. All drug and administration costs
were obtained from relevant sources in the province of Ontario and validated by
PMH. Rituximab dosing was set at 375 mg/m2 for cycle 1 (day 1) and 500 mg/m2 of
cycles 2-6 (day 1). Intravenous F and C were dosed at 25 mg/m2 and 250 mg/m2,
respectively, for 6 cycles (days 1-3). Oral dosing of these drugs was set at 40 mg/m2
and 325 mg/m2, respectively. Drug utilization was estimated based on a body sur-
face area of 1.8 m2. RESULTS: The cost of R-FC PO at PMH is $32,634 per patient
(Drug cost: $29,292; Administration cost: $3,342), while the cost of R-FC IV is $33,400
per patient (Drug cost: $25,192; Administration cost: $8,208). Overall, utilization of
R-FC PO is $766, or 2%, less costly than R-FC IV at PMH. Real-world conditionswould
impact the difference in price between these two options, as patients may tolerate
more treatment cycles of one regimen compared to another. The cost of the PO and
IV routes of administration may be viewed as functionally equivalent at PMH,
making the decision to employ a specific route of administration one that should be
based on non-financial criteria. These results should apply to all Canadian hospi-
tals with drug and administration costs that are similar to those found at PMH.
CONCLUSIONS:This analysis shows that R-FC PO ismarginally less expensive than
R-FC IV at PMH. Therefore, the choice of format should bemade based on patients’
individual needs.
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OBJECTIVES: Therapies for HIV and cancer draw attention due to both high unmet
need and high costs. In some cases, HIV treatments are approaching the prices of
cancer treatments. However these disease states are often reviewed differently by
payers and HTA agencies. NICE, for example, does not perform HTAs for HIV ther-
apies while other European countries do. We examined the relative differences in
prices between HIV and cancer therapies across several European countries to
identify the potential impact of HTA reviews. METHODS: We included therapies
approved for use 2004-2010 in HIV (Atripla, Trizivir, Reyataz, Norvir, Truvada, In-
virase, Celsentri, Isentress, Fuzeon) and cancer (Alimta, Avastin, Erbitux, Sutent,
Tyverb,Taxotere, Nexavar). Current yearly treatment prices (2010) were identified
for all therapies for UK, FR, DE, IT, and ES. Price differentials between the UK and
other countries were determined for each treatment. Mean country price differen-
tials (UK reference) were compared. RESULTS: HIV therapies were on average 30%
(median differential 29%) lower in price in the UK than other countries. Price dif-
ferentials for HIV therapy ranged from 18% (higher price in UK) to 75% (less
expensive in UK). Cancer therapy prices averaged 36% (median 36%) lower in UK
than other countries. Price differentials for HIV therapy ranged from 6% to 80%
(lower price in UK) with amedian of 36%. The apparent discrepancy betweenmean
country differentials was not present if the single HIV therapywasmore expensive
in the UK than other European countries (Norvir was excluded). CONCLUSIONS:
Across 9 HIV therapies and 7 cancer treatments, all treatments were on average
lower in price in the UK. However, the price differential was not substantially
different across the 2 therapy areas. There is little evidence supporting an upward
price pressure due to a lack of economic-driven HTA reviews of HIV products when
compared to oncology therapies.
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OBJECTIVES: Economic analyses of stage III colon cancer (CC) treatments should
account for multiple lines of chemotherapy, yet little is known about the cost
variation between first-line (1stTx) and second-line chemotherapy (2ndTx). This
study investigates the direct medical costs of 1stTx and 2ndTx among elderly
American patientswith stage III CC.METHODS:We included patients over 65 years
and diagnosed with stage III CC from the 1997-2005 Surveillance, Epidemiology,
and End Results (SEER)-Medicare database. 1stTx was defined as any use of 5-flu-
orouracil/leucovorin-only, oxaliplatin-based, or irinotecan-based chemotherapies;
2ndTx was the chemotherapy following the 1stTx after a therapy gap of at least 12
weeks or a switch in chemotherapy. 1stTx and 2ndTx were examined during the
first 40 weeks following chemotherapy initiation. Cost data representing total
Medicare reimbursements were used to calculate weekly costs for the first 26
weeks of each treatment. We further examined the cost difference between pa-
tientswho started 2ndTx early (26weeks) and late (26weeks). RESULTS:Among
18,378 elderly patients with stage III CC, 57% received 1stTx (n10,408). Among
1stTx users, 8% (n870) went on to receive 2ndTx. Average weekly total medical
costs for 1stTx varied between $647 and $1,493 (meanSD$895166) while these
for 2ndTx were higher, ranging from $752 to $2,041 (meanSD$1,046286). Fur-
thermore, average weekly total medical costs of 2ndTx in patients who started
2ndTx early ranged from $900 to $2,093 (meanSD$1,251318), reflecting higher
costs than among late 2ndTx users, whose costs ranged from $767 to $1,483
(meanSD$1,011226). CONCLUSIONS: Average weekly total medical costs of
stage III CC patients were higher for 2ndTx than 1stTx. Early 2ndTx initiators also
had higher average weekly total medical costs than late 2ndTx users. Findings
suggest that directmedical costs of stage III CC patients are lowerwhen they are on
first-line than second-line chemotherapy.
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OBJECTIVES: To compare erythropoiesis-stimulating agent (ESA) dosing patterns
and costs in outpatients with chronic kidney disease (CKD) not on dialysis or with
chemotherapy-induced anemia (CIA).METHODS: Electronic records from the Pre-
mier Perspective Comparative Hospital Database (2006Q1-2009Q3) were analyzed
to identify outpatients18 years old treated with epoetin alfa (EPO) or darbepoetin
alfa (DARB). Patients receiving renal dialysis or treated with both ESAs were ex-
cluded. CKDpatients had1 claim for CKD, no claim for cancer, and did not receive
chemotherapy. CIA patients had1 claim for cancer, received chemotherapy, and
had no claim for CKD. The mean cumulative ESA dose was used to calculate costs,
based on April 2010 wholesale acquisition costs (EPO: $15.15/1,000 Units, DARB:
$4.96/mcg). RESULTS: A total of 11,012 CKD (EPO: 6,921; DARB: 4,091) and 5,590 CIA
(EPO: 2,856; DARB: 2,734) outpatients were identified. EPO patients were slightly
younger than DARB patients in the CKD group (years: 71.0 vs. 71.6; P.0341) and of
similar age in the CIA group (years: 62.2 vs. 62.7; P.1316). The proportion of fe-
males was higher in CKD (EPO 62.2% vs. DARB 58.8%; P.0003) and smaller in CIA
(EPO 63.4% vs. DARB 67.0%; P.0047). The mean treatment duration was slightly
longer for EPO CKD patients (months: 3.6 vs. 3.4, P.0004) and similar for CIA
patients (months: 2.6 vs. 2.5; P.1816). Themean cumulative dose was EPO 137,101
Units and DARB 533 mcg in CKD, and EPO 221,652 Units and DARB 933 mcg in CIA,
yielding dose ratios of 257:1 and 238:1 (Units EPO:mcg DARB), respectively. Corre-
sponding ESA costs were higher for DARB than for EPO in both populations (CKD:
$2,644 vs. $2,077; CIA: $4,627 vs. $3,358). CONCLUSIONS: This analysis reported
dose ratios of 257:1 and 238:1 in CKD and CIA outpatients, respectively. DARB price
premiums of 27% for CKD and 38% for CIA patients were observed.
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OBJECTIVES: Red blood cell transfusion is the standard of care for many patients
with myelodysplastic syndrome (MDS) in the US. Transfusions are economically
burdensome due to the costs associated with the transfusions including iron che-
lation therapy (ICT). This study aimed to investigate potential cost savings associ-
ated with transfusion independence as a result of lenalidomide use.METHODS: A
one-year simulation model was constructed to estimate the relevant costs of using
lenalidomide compared to transfusions in the treatment of MDS patients with a 5q-
deletion and transfusion-dependent anemia. A two arm model was constructed to
simulate patients through the costs of lenalidomide vs. transfusions. Patients were
assigned initial transfusion and ICT requirements, response status, risk of infection,
death, progression to acutemyeloid leukemia (AML), and iron overload complications
(IOC) based on data from a clinical trial and existing literature. Patients who became
transfusion independent were subject to lower risk of infection, death, progression to
AML and elimination of ICT. Dosing frequency andmodification of lenalidomide was
simulated based on results of the MDS-003 clinical trial. Treatment guidelines also
served as a basis of assumptions when required. Resource use and cost data (in 2010
US dollars) were obtained from US databases and available literature. RESULTS: In a
scenario where it was assumed that patients became transfusion independent with
lenalidomide use, a patient’s cost was $119,186 inclusive of the cost of lenalidomide,
whereas the costs for a transfusion dependent patient were $77,729. In this scenario,
patients receiving lenalidomide experienced reduced infections, IOCs, progression to
AML and ICT compared to patients treated with transfusions. CONCLUSIONS: In the
US, treatingMDSpatientswith transfusion-dependent anemia and a 5q-deletionwith
lenalidomide results in cost savings due to a reduction in costs from transfusion re-
lated complications. These savings serve to largely offset lenalidomide treatment
costs.
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OBJECTIVES: To compare long-term costs to Medicare in patients diagnosed with
follicular lymphoma (FL) receiving frontline chemotherapy /- rituximab.
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